ROQUEFORT THERAPEUTICS PLC

Share Issue/Capital Change • Dec 1, 2025

National Storage Mechanism | Additional information

RNS Number : 6886J

Roquefort Therapeutics PLC

01 December 2025

1 December 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Ex-Entitlement Date - Unlisted Redeemable Non-Voting Shares

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares ("Unlisted RNV Shares") has now passed, its ordinary shares will be marked ex-entitlement in respect of the Unlisted RNV Shares with effect from the commencement of trading today, 1 December 2025.

Accordingly, all holders of ordinary shares and convertible loan notes who were on the Company's register as at close of business on 28 November 2025 will be eligible to receive the Unlisted RNV Shares. In addition, anyone who purchased ordinary shares on Friday, 28 November 2025 will also be eligible to receive the Unlisted RNV Shares.

A detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

ENDS

Enquiries:

Roquefort Therapeutics plc	+44 (0)20 3918 8633
Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
SP Angel Corporate Finance LLP (Broker to the Company) David Hignell / Vadim Alexandre / Devik Mehta	+44 (0)20 3470 0470
Shard Capital Partners LLP (Broker to the Company) Damon Heath	+44 (0)20 4530 6926
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper	+44 (0)20 7466 5000

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FURUAORRVOUURAA